MoonLake https://validator.w3.org/feed/docs/rss2.html Homepage Citi’s 2026 Biopharma Back to School Conference 3rd Annual Guggenheim Healthcare Innovation Conference Science 8th Annual Wolfe Research Healthcare Conference ACR Convergence 2026 SHSA 2026 EADV Congress 2026 Stifel 2026 Virtual Immunology and Inflammation Forum Morgan Stanley 24th Annual Global Healthcare Conference 28th Annual Global Investment Conference Cantor Global Healthcare Conference VP Market Access & Pricing VP Marketing Senior Director Analytics, Performance and Forecasting Senior Specialist Drug Product and Device (GxP) Therapeutic Focus Senior Specialist/ Associate Manager, Medical Affairs (Fixed-Term Contract) Strategy, Contracting & Pricing Lead Senior Specialist Contract Management, AI & Compliance Manager Clinical Operations Associate Manager Payroll and Employee Benefits Finance Manager IT Data Integration & Platforms Director Insights & Performance Analytics Director / Senior Director Payer Marketing Careers MoonLake Immunotherapeutics reports on week 16 results of the VELA Phase 3 hidradenitis suppurativa program with the Nanobody® sonelokimab Payer Account Team Lead Privacy Policy & Cookie Notice Privacy Notice for Healthcare Professionals Contact us MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab Pipeline Header – Test MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update About us Psoriatic arthritis (PsA) MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026 Psoriasis (PsO) Palmoplantar pustulosis (PPP) MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results